Twin Health has launched a new GLP-1 Stewardship Model aimed at helping employers and health plans manage the growing cost and long-term use of GLP-1 weight loss medications. Built on the company’s Digital Twin Care Platform, the model uses AI-driven metabolic monitoring to personalize treatment plans, guide patients through therapy and determine when medications can be safely reduced or discontinued. The approach is designed to shift the focus from indefinite drug utilization toward long-term health outcomes and sustainable weight management.
The company argues that many current GLP-1 care models lack clear strategies for tapering or discontinuing treatment, often leaving patients on expensive therapies indefinitely. Twin’s model introduces structured oversight across the full treatment journey, from eligibility assessment to maintenance and eventual discontinuation when clinically appropriate. Employers can choose from several coverage approaches, including program-gated access, defined spending caps and direct-to-consumer pathways, giving organizations more flexibility in managing pharmacy costs while still supporting employee access to care.
At the center of the platform is Twin’s AI-powered Digital Twin technology, which continuously analyzes biometric and behavioral data—including glucose levels, weight, activity and lab results—to provide personalized recommendations and help clinicians adjust care in real time. According to the company, clinical trial data showed that most participants were able to discontinue GLP-1 medications while maintaining or improving weight loss outcomes. More broadly, the launch reflects increasing efforts across healthcare to balance access to high-demand GLP-1 therapies with long-term affordability, clinical oversight and sustainable care models.
Click here to read the original news story.
